NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 635715-01-4
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of inotuzumab ozogamicin during breastfeeding. Because inotuzumab ozogamicin is a large protein molecule with a molecular weight of 168,000 Da and its active metabolite is 97% plasma protein bound, the amount in milk is likely to be very low. However, the half-life of inotuzumab ozogamicin is about 12.3 days and it might accumulate in the infant. Until more data become available, inotuzumab ozogamicin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during inotuzumab ozogamicin therapy for at least 2 months after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Inotuzumab Ozogamicin
CAS Registry Number
635715-01-4
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Obinutuzumab[Drugs and Lactation Database (...]Review Obinutuzumab. Drugs and Lactation Database (LactMed). 2006
- Review Nivolumab[Drugs and Lactation Database (...]Review Nivolumab. Drugs and Lactation Database (LactMed). 2006
- Review Bezlotoxumab[Drugs and Lactation Database (...]Review Bezlotoxumab. Drugs and Lactation Database (LactMed). 2006
- Review Dinutuximab[Drugs and Lactation Database (...]Review Dinutuximab. Drugs and Lactation Database (LactMed). 2006
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.[Lancet Haematol. 2017]Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, et al. Lancet Haematol. 2017 Aug; 4(8):e387-e398. Epub 2017 Jul 4.
- Inotuzumab Ozogamicin - Drugs and Lactation Database (LactMed)Inotuzumab Ozogamicin - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...